Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer

NCT02162667 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT02162667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02162667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer
Lead sponsor
Celltrion
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2014
Completion date
October 31, 2018
Enrollment
562 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive carcinoma of breast